ストックスクリーナーアプリを入手
100.05
8.24%
-8.98
アフターアワーズ：
99.60
-0.45
-0.45%
Incyte Corp (INCY) 最新ニュース
Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Incyte (INCY) Reports Strong Q4 and Annual Revenue Growth - GuruFocus
Incyte Corp (INCY) Q4 2025 Earnings Call Highlights: Strong Reve - GuruFocus
Incyte (INCY) Shares Fall After Q4 Earnings Miss and Weak 2026 Outlook - GuruFocus
Jefferies reiterates Buy rating on Incyte stock, maintains $120 price target - Investing.com
Why Incyte (INCY) Stock Is Nosediving - Finviz
INCY Q4 Earnings Miss Estimates, Revenues Beat on Higher Product Sales - Finviz
Incyte (INCY) Releases Product Revenue and Expense Guidance for 2026 - GuruFocus
Truist Securities reiterates Hold rating on Incyte stock, maintains $103 target - Investing.com
Incyte Q4 2025 slides: Revenue surges 28%, stock dips on EPS miss - Investing.com
Incyte (INCY) Faces Challenges with Opzelura as Jakafi Patent Expiry Looms - GuruFocus
Earnings call transcript: Incyte’s Q4 2025 revenue beats estimates, stock dips - Investing.com
Incyte (NASDAQ:INCY) Posts Quarterly Earnings Results, Misses Estimates By $0.16 EPS - MarketBeat
Incyte (NASDAQ:INCY) Surprises With Q4 CY2025 Sales - Finviz
Incyte Corp. (NASDAQ:INCY) Reports Mixed Q4 2025 Results with Revenue Beat and EPS Miss - Chartmill
Incyte weak 2026 revenue forecast heightens Jakafi patent concerns - Reuters
Incyte: Q4 Earnings Snapshot - kens5.com
Incyte (INCY) Q4 Revenue Surpasses Estimates Despite EPS Miss - GuruFocus
Incyte (INCY) Q4 2025 Earnings Call Transcript - The Globe and Mail
Incyte shares fall as Q4 earnings miss overshadows revenue beat - Investing.com
Incyte shares fall as Q4 earnings miss overshadows revenue beat By Investing.com - Investing.com South Africa
Incyte earnings missed by $0.11, revenue topped estimates - Investing.com
Incyte earnings missed by $0.11, revenue topped estimates By Investing.com - Investing.com South Africa
Incyte Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
Earnings Breakdown: Incyte Q4 - Benzinga
Why Incyte (NASDAQ:INCY) Appears in Nasdaq Composite Index Coverage? - Kalkine Media
A Look Ahead: Incyte's Earnings Forecast - Benzinga
Incyte earnings up next: Can pipeline ease Jakafi reliance? - Investing.com
Incyte (INCY) Q4 Earnings: What To Expect - Finviz
Piper Sandler Raises Incyte (INCY) Price Target to $110 | INCY S - GuruFocus
Incyte sets February 10 call to unveil Q4 and full-year 2025 results - MSN
Incyte Gears Up to Report Q4 Earnings: Is a Beat in the Cards? - Finviz
How Investors Are Reacting To Incyte (INCY) EMA Backing For Zynyz Combo In First-Line Anal Cancer - simplywall.st
Incyte’s Zynyz Wins CHMP Backing And Opens New EU Opportunity - simplywall.st
This Incyte Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday - Benzinga
Incyte (INCY) Receives New "Buy" Rating and Price Target of $135 - GuruFocus
Incyte’s Transition From A Jakafi Company To A More Diversified Pharma - Citeline News & Insights
A Glimpse Into The Expert Outlook On Incyte Through 8 Analysts - Benzinga
Barclays Maintains Overweight Rating on INCY, Raises Price Targe - GuruFocus
TD Cowen Keeps Buy Rating on Incyte (INCY), Cites Roadmap to Triple Non-Jakafi Revenue by 2029 - Finviz
Analysts differ in opinion on Jakafi drug maker Incyte (INCY) - MSN
Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth - Finviz
Prelude climbs as FDA clears study for Incyte-partnered cancer candidate - Seeking Alpha
FDA clears Prelude trial drug for polycythemia vera and myelofibrosis - stocktitan.net
Analysts Differ in Opinion on Jakafi Drug Maker Incyte (INCY) - Finviz
Incyte (INCY) to Release Earnings on Tuesday - MarketBeat
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC) - BioSpace
Value Investing Opportunity: Incyte Corp. (NASDAQ:INCY) Presents a Compelling Case - Chartmill
Incyte (INCY) Gains European Recommendation for Zynyz Therapy - GuruFocus
Incyte (INCY) Gains EMA Panel Support for Expanded Use of Zynyz - GuruFocus
Incyte wins EU backing for MacroGenics-partnered cancer drug in GIT indication - Seeking Alpha
Incyte gets positive CHMP opinion for anal cancer drug Zynyz - StreetInsider
Ruffer LLP Has $3.74 Million Holdings in Incyte Corporation $INCY - MarketBeat
Undercovered Dozen: Incyte, Annaly Capital, ImmunityBio And More - Seeking Alpha
Incyte to Report Fourth Quarter and Year-End 2025 Financial Results - Chartmill
INCY Stock Price and Chart — NASDAQ:INCY - TradingView
Here's Why Incyte (INCY) is a Strong Momentum Stock - Yahoo Finance
Incyte Corporation $INCY Stock Position Lowered by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
1.16%
0.36%
大文字化:
|
ボリューム (24 時間):